Adverse Events and Clinical Pearls on TKI Utilization in CML

Jorge Cortes, MD, provides clinical insights on the utilization of TKIs in CML and outlines associated adverse events.

CN_TA_Cortes_Seg05_AEs

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Patient Workup and Risk Stratification

EP: 2.Treatment Algorithm for Chronic Phase CML

EP: 3.Treating Patients with CML Following Progression

EP: 4.Accelerated Phase CML Treatment Practices

Now Viewing

EP: 5.Adverse Events and Clinical Pearls on TKI Utilization in CML

Recent Videos

Treatment Selection, Sequencing, and Supportive Care for Brain Metastases in HER2+ mBC

Local and Systemic Approaches in Treating Brain Metastases in HER2+ mBC: The Role of Radiation and SRS

Biomarkers and Clinical Features Guiding HER2-Directed Therapy in Upper GI Cancer

Trastuzumab Deruxtecan in HER2+ Gastric Cancer: Insights From DESTINY-Gastric02

Deciding Which RP to Utilize

Making Sense of PARP Inhibitors

Consideration for Other Androgen Receptor Inhibitors

Prostate Cancer in 2025

Clinical Pearls: Synthesizing Risk Assessment and Response Patterns in Advanced RCC Management

Auto-SCT or CAR T? A Case-Based Discussion in Relapsed DLBCL